Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors

Research output: Review article

17 Citations (Scopus)

Abstract

Excessive stimulation of AMPA type ionotropic glutamate receptors is increasingly implicated in the development and maintenance of several debilitating human CNS disorders. Preliminary results of Phase II clinical trials have shown that talampanel, a new negative allosteric modulator of AMPA receptors with homophthalazine (2,3-benzodiazepine) chemical structure, can be useful for the treatment of epilepsy and might alleviate dyskinesia in levodopa-treated patients with Parkinson's disease. Data of animal experiments give promise that talampanel might also be suitable for the treatment of ischaemic stroke and multiple sclerosis and might also suppress tumor growth in the CNS that makes this chemical structure an exciting new field of pharmaceutical research.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalDrug Discovery Today: Therapeutic Strategies
Volume1
Issue number1
DOIs
Publication statusPublished - szept. 2004

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors'. Together they form a unique fingerprint.

  • Cite this